Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886493 | PMC |
| http://dx.doi.org/10.1002/ajh.27591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
For older patients with competing comorbidities, optimizing oncologic therapies is of paramount importance. Circulating tumor DNA (ctDNA) may provide a strategy to identify which patients who may safely de-escalate certain therapies. In this prospective, hybrid-decentralized trial ( NCT05914792 ) that integrated clinical outcomes, patient- and caregiver-reported outcomes, and correlative tissue analysis, the primary objective was to determine if ctDNA levels were associated with tumor progression in older patients who opted to forgo upfront surgery in favor of primary endocrine therapy (pET).
View Article and Find Full Text PDFDialectical behavior therapy skills training for African American pregnant women with ACEs: a pilot study of feasibility, acceptability, and mental health barriers and attitudes.
Eur J Psychotraumatol
December 2025
Rollins School of Public Health, Atlanta, GA, USA.
Toxic stress contributes to socioeconomic and racial health disparities that persist across generations. Developing and implementing prenatal interventions that reduce toxic stress and associated comorbidities is warranted. Dialectical Behavior Therapy (DBT) Skills Training group interventions have demonstrated efficacy for depression and posttraumatic stress disorder (PTSD) and are scalable in diverse settings.
View Article and Find Full Text PDFKidney function decline in cT1a patients treated with Microwave Ablation versus Partial Nephrectomy.
Kidney Cancer J
September 2024
University of Virginia School of Medicine, Department of Public Health Sciences, 200 Jeanette Lancaster Way, Charlottesville, VA 22903.
Background: Microwave ablation (MWA) is an emerging treatment modality for clinical T1a (cT1a) small renal masses (SRM) with studies showing it has comparable oncological outcomes to partial nephrectomy (PN). However, more research is needed to the impact of each treatment on kidney function decline.
Objective: To compare the progression of kidney function decline in patients with cT1a SRM treated with MWA or PN.
Treatment outcome is associated with pre-treatment connectome measures across psychiatric disorders - evidence for connectomic reserve?
Neuroimage Clin
August 2025
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Psychiatry, de Boelelaan 1117, Amsterdam, the Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Anatomy and Neurosciences, de Boelelaan 1117, Amsterdam, the Netherlands; Compulsivity, Impulsivity and Attention, Amsterda
Predicting treatment efficacy in psychiatric disorders remains challenging, despite the availability of effective interventions. Previous studies suggest a link between pre-treatment brain network characteristics and treatment efficacy in individual disorders, but cross-disorder investigations are lacking. We analyzed pre-treatment MRI data from 177 individuals (113 females) with either obsessive-compulsive disorder (OCD) or post-traumatic stress disorder with comorbid personality disorders (PTSD) that received different non-pharmacological treatments.
View Article and Find Full Text PDFReal-world outcomes of neoadjuvant chemotherapy for advanced ovarian cancer: What happens to patients who never undergo surgery?
Gynecol Oncol
August 2025
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, United States of America. Electronic address:
Objectives: To describe the outcomes of patients with advanced ovarian cancer (OC) treated with neoadjuvant chemotherapy who do and do not undergo interval cytoreductive surgery (ICS).
Methods: This was a retrospective cohort study of patients with stage III/IV epithelial OC who began treatment with at least three cycles of chemotherapy from 2017 to 2022. Primary analysis compared 3-year progression-free (PFS) and overall (OS) survival for patients who underwent ICS to those who received chemotherapy only (planned ICS not performed).